The effect of imatinib mesylate (Glivec) on human tumor-derived cells

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 649-655

  Knight, Louise A ^a   Nicolantonio, Federica Di ^a   Whitehouse, Pauline A ^a   Mercer, Stuart J ^a   Sharma, Sanjay ^a   Glaysher, Sharon ^a   Hungerford, John L ^b   Hurren, Jeremy ^a   Lamont, Alan ^c   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c SOUTHEND HOSPITAL   (United Kingdom)

Author keywords

ATP tumor chemosensitivity assay; Chemosensitivity; Glivec; Imatinib

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; IMATINIB; NAVELBINE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TAXANE DERIVATIVE; TREOSULFAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UVEA MELANOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 33747627127     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000215062.16308.41     Document Type: Article

References (27)

1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-3356.
2. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38:S28-S36.
3. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79:1283-1316.
4. Matei D, Chang DD, Jeng M-H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004; 10:681-690.
5. Paner GP, Silberman S, Hartman G, Micetich KC, Aranha GV, Alkan S. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res 2003; 23:2253-2260.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
7. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20:325-334.
8. Ning Z-Q, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001; 97:3559-3567.
9. Hou L, Panthier J, Arnheiter H. Signaling and transcriptional regulation in the neural crest-derived melanocyte lineage: interactions between KIT and MITF. Development 2000; 127:5379-5389.
10. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992; 7:51-56.
11. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003; 2:1.
12. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, et al. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci 2004; 45:2075-2082.
13. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, et al. Roles of stem cell factor/c-Kit and effects of Glivec®/STI571 in human uveal melanoma cell tumourigenesis. J Biol Chem 2004; 279:31769-31779.
14. Duskin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Curr Treat Options Oncol 2005; 6:115-120.
15. Pereira P, Odashiro A, Marshall J, Correa Z, Belfort R, Burnier M. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog 2005; 14:19.
16. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
17. Cree IA. Luminescence-based cell viability testing. In: LaRossa RA, editor. Bioluminescence methods and protocols. Totowa: Humana Press; 1998. pp. 169-177.
18. Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001; 11:601-609.
19. Hunter EM, Sutherland LA, Cree IA, Subedi AM, Hartmann D, Linder D, Andreotti PE. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anticancer Drugs 1994; 5:171-176.
20. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, et al. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 2004; 4:83.
21. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347:1066-1071.
22. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19:931-942.
23. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, et al. GEICAM Group. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15:79-87.
24. Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004; 53:433-438.
25. Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52:6139-6143.
26. Gutman M, Singh RK, Radinsky R, Bar-Eli M. Intertumoural heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 1994; 14:1759-1765.
27. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G. Sensitivity testing of human tumours using a microplate ATP assay. In: Cambell AC, Stanley PE, Kricka LJ, editors. Chemiluminescence and bioluminescence. Chichester: Wiley; 1994. pp. 403-406.